目的 了解海南省人民醫(yī)院2012—2019年重點(diǎn)監(jiān)控藥物的臨床使用情況，為安全、有效、經(jīng)濟(jì)的藥品使用提供參考。方法 采用回顧性分析方法收集海南省人民醫(yī)院2012年1月—2019年12月重點(diǎn)監(jiān)控藥物處方，分析重點(diǎn)監(jiān)控藥物的處方占比、使用人次占比、種類、使用金額和科室占比。結(jié)果 海南省人民醫(yī)院2012—2019年重點(diǎn)監(jiān)控藥物的處方占比和使用人次占比逐年下降；在26種重點(diǎn)監(jiān)控藥物中，以復(fù)合輔酶、二丁酰環(huán)磷腺苷鈣、馬來酸桂哌齊特、前列地爾和丹參川芎嗪處方數(shù)較多；而單唾液酸四己糖神經(jīng)節(jié)苷脂鈉、二丁酰環(huán)磷腺苷鈣、馬來酸桂哌齊特、前列地爾和依達(dá)拉奉的使用金額較多；重點(diǎn)監(jiān)控藥物的使用多集中于醫(yī)療保健、心血管內(nèi)科、神經(jīng)內(nèi)科、神經(jīng)外科、胃腸外科、脊柱外科、兒科和老年病科等。結(jié)論 海南省人民醫(yī)院2012—2019年的重點(diǎn)監(jiān)控藥物使用有所控制，然而部分藥物如復(fù)合輔酶和部分科室如兒科對重點(diǎn)監(jiān)控藥物的應(yīng)用仍需密切關(guān)注。

Objective To investigate the prevalence of key monitoring drugs in Hainan General Hospital from 2012 to 2019 to improve the rational use of key monitoring drug. Methods The prescriptions of key monitored drugs in Hainan Provincial People's Hospital from January 2012 to December 2019 were collected by retrospective analysis, and the proportion of prescriptions, the proportion of patients, types, consumption sum and department proportion of key monitored drugs were analyzed. Results From 2012 to 2019, the proportion of prescriptions and times of key monitored drugs in Hainan Provincial People's Hospital decreased year by year. Among 26 key monitoring drugs, compound coenzyme, dibutyryl cyclic adenosine calcium, cinnampiazide maleate, alpropil and salvia miltiorrhiza ligustrazine were the most frequently prescribed drugs. The amount of sodium monosialate tetrohexose ganglioside, calcium dibutyl cyclic adenosine phosphate, cinnampiazide maleate, alprostadil and edaravone were higher. The use of key monitoring drugs is mainly concentrated in medical care, cardiovascular medicine, neurology, neurosurgery, gastrointestinal surgery, spine surgery, pediatrics and geriatrics. Conclusion The utilization of key monitoring drugs in Hainan General Hospital was controlled from 2012 to 2019. However, some drugs such as compound coenzyme and some departments such as pediatrics still need to pay close attention to the application of key monitored drugs.

R95

海南省自然科學(xué)基金資助項(xiàng)目（819QN224）